Mehdi Karoui

Mehdi Karoui

Auto-generated profile, based on publicly available information

Mehdi Karoui

Department of Surgery, Hôpital Européen Georges-Pompidou, Paris, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
T(the French Research Group of Rectal Cancer Surgery (GRECCAR)
the French Research Group of Rectal Cancer Surgery (GRECCAR)
BLBernard Lelong
Bernard Lelong
CCCécile de Chaisemartin
Cécile de Chaisemartin
HMHelene Meillat
Helene Meillat
SCSandra Cournier
Sandra Cournier
JDJean Robert Delpero
Jean Robert Delpero
Total mesorectal excision is the standard surgical treatment for mid- and low-rectal cancer. Laparoscopy represents a clear leap forward in the management of rectal cancer patients, offering significant improvements in post-operative measures such as pain, first bowel movement, and hospital length of stay. However, there are still some limits to its applications, especially in difficult cases. Such cases may entail either conversion to an open procedure or positive resection margins. Transanal endoscopic proctectomy (ETAP) was recently described and could address the difficulties of approaching the lower third of the rectum. Early series and case-control studies have shown favourable short-term results, such as a low conversion rate, reduced hospital length of stay and oncological outcomes comparable to laparoscopic surgery. The aim of the proposed study is to compare the rate of positive resection margins (R1 resection) with ETAP versus laparoscopic proctectomy (LAP), with patients randomly assigned to each arm. The proposed study is a multicentre randomised trial using two parallel groups to compare ETAP and LAP. Patients with T3 lower-third rectal adenocarcinomas for whom conservative surgery with manual coloanal anastomosis is planned will be recruited. Randomisation will be performed immediately prior to surgery after ensuring that the patient meets the inclusion criteria and completing the baseline functional and quality of life tests. The study is designed as a non-inferiority trial with a main criterion of R0/R1 resection. Secondary endpoints will include the conversion rate, the minimal invasiveness of the abdominal approach, postoperative morbidity, the length of hospital stay, mesorectal macroscopic assessment, functional urologic and sexual results, faecal continence, global quality of life, stoma-free survival, and disease-free survival at 3 years. The inclusion period will be 3 years, and every patient will be followed for 3 years. The number of patients needed is 226. There is a strong need for optimal evaluation of the ETAP because of substancial changes in the operative technique. Assessment of oncological safety and septic risk, as well as digestive and urological functional results, is particularily mandatory. Moreover, benefits of the ETAP technique could be demonstrated in post-operative outcome. ClinicalTrial.gov: NCT02584985 . Date and version identifier: Version n°2 – 2015 July 6.

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CSCarine El Sissy
Carine El Sissy
AKAmos Kirilovsky
Amos Kirilovsky
CPChristine Lagorce Pagès
Christine Lagorce Pagès
FMFlorence Marliot
Florence Marliot
PCPetra A. Custers
Petra A. Custers
FPFranck Pagès
Franck Pagès
PURPOSE: No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance of the Immunoscore biopsy (ISB) was recently suggested in a preliminary study. METHODS: This international validation study included 249 patients with clinical complete response (cCR) managed by W&W strategy. Intratumoral CD3+ and CD8+ T cells were quantified on pretreatment rectal biopsies by digital pathology and converted to ISB. The primary end point was time to recurrence (TTR; the time from the end of neoadjuvant treatment to the date of local regrowth or distant metastasis). Associations between ISB and outcomes were analyzed by stratified Cox regression adjusted for confounders. Immune status of tumor-draining lymph nodes (n = 161) of 17 additional patients treated by neoadjuvant chemoradiotherapy and surgery was investigated by 3'RNA-Seq and immunofluorescence. RESULTS: Recurrence-free rates at 5 years were 91.3% (82.4%-100.0%), 62.5% (53.2%-73.3%), and 53.1% (42.4%-66.5%) with ISB High, ISB Intermediate, and ISB Low, respectively (hazard ratio [HR; Low v High], 6.51; 95% CI, 1.99 to 21.28; log-rank P = .0004). ISB was also significantly associated with disease-free survival (log-rank P = .0002), and predicted both local regrowth and distant metastasis. In multivariate analysis, ISB was independent of patient age, sex, tumor location, cT stage (T, primary tumor; c, clinical), cN stage (N, regional lymph node; c, clinical), and was the strongest predictor for TTR (HR [ISB High v Low], 6.93; 95% CI, 2.08 to 23.15; P = .0017). The addition of ISB to a clinical-based model significantly improved the prediction of recurrence. Finally, B-cell proliferation and memory in draining lymph nodes was evidenced in the draining lymph nodes of patients with cCR. CONCLUSION: The ISB is validated as a biomarker to predict both local regrowth and distant metastasis, with a gradual scaling of the risk of pejorative outcome.

8 January 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NDNicola De'Angelis
Nicola De'Angelis
DMDiane Mege
Diane Mege
CSCharles Sabbagh
Charles Sabbagh
GMGilles Manceau
Gilles Manceau
VBValérie Bridoux
Valérie Bridoux
MKMehdi Karoui
Mehdi Karoui

13 February 2021 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
MKMehdi Karoui
Mehdi Karoui
CGClaire Gallois
Claire Gallois
GPGuillaume Piessen
Guillaume Piessen
JLJean‐Louis Legoux
Jean‐Louis Legoux
EBEmilie Barbier
Emilie Barbier
TIThe PRODIGE 22 investigators/Collaborators
The PRODIGE 22 investigators/Collaborators

1 October 2018 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
DMDiane Mege
Diane Mege
GMGilles Manceau
Gilles Manceau
LBLaura Beyer-Berjot
Laura Beyer-Berjot
VBValérie Bridoux
Valérie Bridoux
ZLZaher Lakkis
Zaher Lakkis
KFKévin Fixot
Kévin Fixot

1 August 2021 in ESMO Open
Verified
Journal Article
Open access
Julien TaiebJulien Taieb
Julien Taieb
MKM. Karoui
M. Karoui
DBDebora Basile
Debora Basile
Stage II colon cancer (CC) is probably one of the best prognosis gastrointestinal tumors seen in our consultations, but often takes a lot of time for physicians to determine appropriate treatment because of the limited benefit of adjuvant chemotherapy (CT) in these patients, together with the limited evidence in this situation. How to choose the best treatment for each individual patient is thus dependent on molecular (microsatellite instability/microsatellite stability status) and clinico-pathological features relevant enough to classify these tumors into low-, intermediate- and high-risk stage II disease and to choose an appropriate attitude for each of these subgroups. In practice, the first step in treatment decision making must be to assess the patient's status and comorbidities to see if the patient is eligible for an adjuvant treatment. Then, as fluoropyrimidines (FPs) are the corner stone of CC adjuvant treatment, screening for dihydropyrimidine dehydrogenase deficiency is mandatory in western countries. Finally, depending on the patient's characteristics and tumor risk stage, the strategy may be surveillance, adjuvant FP alone or oxaliplatin-based adjuvant CT. In the near future, new tools such as Immunoscore® (HalioDx; Luminy Biotech Enterprises, Marseille Cedex, France) and circulating tumor DNA may help to identify more precisely patients with minimal residual disease for more personalized adjuvant treatment approaches.